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Background: The diagnosis of sarcoidosis is still a significant challenge in China because of the need to exclude
other diseases including granulomatous infections and malignancies that may be clinically and radiographically
similar. The specific aim of the study is to search for serum protein biomarkers of sarcoidosis and to validate their
clinical usefulness in differential diagnosis.
Methods: Serum samples were collected from patients with sarcoidosis (n = 37), and compared to those from
patients with tuberculosis (n = 20), other pulmonary diseases (n = 20), and healthy volunteers (n = 20) for
determination of sarcoidosis-specific or -associated protein expression profiles. The first part of this study focused
on proteomic analysis of serum from patients with sarcoidosis to identify a pattern of peptides capable of
differentiating the studied populations using the ClinProt profiling technology based on mass spectrometry.
Enzyme Linked Immunosorbent Assay (ELISA) was then used to verify corresponding elevation of the serum protein
concentration of the potential biomarkers in the same patients sets. Receiver operating characteristic curve (ROC)
analyses was performed to determine the optimal cutoff value for diagnosis. Immunohistochemistry was carried out
to further confirm the protein expression patterns of the biomarkers in lung tissue.
Results: An unique protein peak of M/Z 3,210 Daltons (Da) was found to be differentially expressed between the
sarcoidosis and control groups and was identified as the N-terminal peptide of 29 amino acids (94-122) of serum
amyloid A (SAA). ELISA confirmed that the serum SAA level was significantly higher in the sarcoidosis group than
that of the other 3 control groups (p < 0.05). The cutoff for serum SAA concentration determined by ROC analysis
was 101.98 ng/ml, with the sensitivity and specificity of 96.3% and 52.5%, respectively. Immunohistochemical
staining showed that the SAA depositions in lung tissue of the sarcoidosis patients were also significantly more
intense than in non-sarcoid lung tissue (p < 0.05).
Conclusion: This is the first study to investigate serum protein markers in Chinese subjects with sarcoidosis. This
study shows that the serum SAA expression profiles were different between the sarcoidosis and non-sarcoidosis
groups. SAA may be a potential serum biomarker for ruling-out the diagnosis of sarcoidosis in Chinese subjects.
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Sarcoidosis is a systemic disease of unknown etiology,
with the pathological feature of non-caseous epithelioid
granulomas. Many organs could be involved, and espe-
cially the lung and intrathoracic lymph nodes [1,2]. Sar-
coidosis is a diagnosis of exclusion because of its similarity
in the clinical presentations to other lung diseases (such
as tuberculosis, fungal infections, lung cancer, and
cryptogenic organizing pneumonia) [3]. The confirma-
tory diagnosis of sarcoidosis is established only when
clinicoradiographic findings are supported by histo-
logical evidence of non-caseating granulomatous in-
flammation and other causes of granulomas and local
reactions have been reasonably excluded [2,3]. China
has a high prevalence of TB, which results in a signifi-
cant challenge in differentiating sarcoidosis from other
granulomatous lung diseases especially in cases of smear
negative tuberculosis [4,5]. Thereby highly sensitive and
selective serum biomarker assay will be useful for the
diagnosis of sarcoidosis.
Although great efforts have been devoted to establish
methodologies that can differentiate sarcoidosis from
other lung diseases [4-7], the diagnosis of sarcoidosis
still requires histological confirmation of the presence of
granulomatous inflammation and at the same time to
exclude other potential causes of granulomatous inflam-
mation. However, tissue biopsy is cost-prohibitive and
invasive, and the patients with sarcoidosis presenting
with pulmonary findings that are suggestive of sarcoid-
osis often are not diagnosed until much later, resulting
in delay in treatment, and this may be especially detri-
mental if the final diagnosis turns out to be an infectious
process (TB) or cancer. Therefore, a less invasive, less
expensive, sensitive and specific test with a rapid turn-
around time would be clinically useful for the early
diagnosis of sarcoidosis. Serum markers that can be
measured conveniently, such as serum amyloid A
(SAA), soluble interleukin-2 receptor (sIL-2R), lyso-
zyme, angiotensin-converting enzyme (ACE), and the
glycoprotein KL-6, have been reported [6-8]. However,
no single biomarker is sufficiently sensitive and specific
to be recommended for clinical use [8].
Differential proteomics is the systematic investigation
of changes in patterns of serum proteins in diseases [9].
New technologies used in proteomics research such as
the ClinProt profiling technology (a Matrix-Assisted
Laser Desorption/ Ionization Time of Flight Mass Spec-
trometry (MALDI-TOF-MS) combined with magnetic
beads for capture of analyte), have been widely used in
the search for novel diagnostic biomarkers and as thera-
peutic targets. Biomass spectrometry is featured with
high-throughput, high-sensitivity and high-resolution,
and therefore has been used for exploring the differential
protein expression patterns in serum. Substantial progresseshave been made in cancer and autoimmune diseases diag-
nosis using the technology of mass spectrometry [10,11].
In the first part of this study, we used ClinProt profil-
ing technology to discovery serum protein biomarkers
associated with sarcoidosis. Serum amyloid A (SAA) was
increased in the serum of patients with sarcoidosis,
compared with non-sarcoidosis groups including healthy
controls.
Serum amyloid A (SAA) is a protein that is secreted by
the liver during an acute phase of inflammation [12-20].
The association of SAA and sarcoidosis has been previ-
ously reported [13-15,18,19]. In 1989, Rubinstein et. al.
measured SAA concentrations in 25 sarcoidosis patients
and 94 healthy volunteers. This study showed that SAA
concentrations increased significantly in the sarcoidosis
group as compared to the healthy volunteers [13]. An
Italian study also found that serum concentrations of
SAA were significantly higher in sarcoidosis patients
than in healthy controls [15]. However, previous related
studies had only enrolled healthy volunteers as control.
In addition to sarcoidosis, SAA is also associated with
other diseases such as tuberculosis, chronic obstructive
pulmonary disease (COPD) and lung cancer, all of which
may have elements of inflammatory reaction in their
pathophysiology [16-18]. Recently, Chen ES and colleagues
proposed SAA as a key regulator of granulomatous inflam-
mation in Sarcoidosis [14], hence, any new study should
also include non-sarcoid inflammatory lung diseases as
comparator groups. As existing studies have originated
from North America and from Europe, SAA have also not
been investigated in a cohort of Chinese saroidosis patients.
On the second part of the study we evaluated the ef-
fectiveness of SAA as a diagnostic biomarker of Chinese
sarcoidosis compared with non-sarcoidosis groups that
include healthy controls and patients with tuberculosis,
interstitial lung diseases and lung cancer.Patients and methods
Patients and diagnostic criteria
Patients with tissue proven sarcoidosis, tuberculosis (TB),
or other lung diseases (including chronic obstructive pul-
monary disease (COPD), interstitial lung disease and lung
cancer) who were evaluated at the Shanghai Pulmonary
Hospital between September 2008 and April 2010 were
recruited into this study. 26 healthy volunteers were also
enrolled as normal controls. Demographics of the study
subjects are presented in Table 1.
The proposed study was approved by Biomedical Ethics
Review (No. 2011-FK-10) of the Department of Medicine
and Life Sciences, Tongji University School of Medicine.
Informed consent was obtained from each patient who
underwent blood draw for serum analysis and tissue bi-
opsy prior to inclusion in this study.
Table 1 Demographic information of subjects recruited for serum studies
Category Sarcoidosis group Control subjects
Healthy group Tuberculosis group Other pulmonary disease group
Total subjects, n 64* 26 35 38▲
Age, years 48 49 45 46
Gender
Male 24 10 13 14
Female 40 16 22 24
CXR stage 0/18/38/8/0 N/A N/A N/A
0/I/II/III/IV §
§ CXR = chest X-ray; N/A = not applicable; CXR stage: 0 = no adenopathy, no lung infiltrates; stage I = hilar & mediastinal adenopathy only; stage II = hilar &
mediastinal adenopathy plus lung infiltrates; stage III = lung infiltrates only; stage IV = pulmonary fibrosis.
* All of the 64 case, 44 were not being treated, 20 were treated with corticosteroid, CXR stage as stated.
▲ Other Pulmonary Disease Group including 10 cases of interstitial lung disease, 7 cases of chronic obstructive pulmonary disease (COPD), and 11 cases of
lung cancer.
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Fasting specimen of 5 ml of peripheral venous blood was
drawn from each subject, and placed at room temperature
for 30-60 minutes. After centrifugation at 3,000 rpm for
15 minutes, the serum was dispensed into as an aliquot of
0.5 ml/vial for storage at -80°C till they were assayed.
MS analysis and statistical processing
For the ClinProt system proteomics analysis, serum sam-
ples were collected from patients with sarcoidosis (n = 37),
patients with tuberculosis (n = 20), patients with other pul-
monary diseases (n = 20), and healthy volunteers (n = 20)
for determination of sarcoidosis-specific or -associated pro-
tein expression profiles. Before ClinProt system (Bruker
Daltonics Inc., USA) analysis, the serum samples were
pre-treated with Profiling Kit 100 MB-WCX following
the manufacturer's protocol. The limit of molecular weight
(Mr) error of the ClinProt system for data acquisition
was set at <0.1% prior to the procedure. Angiotensin-II
(containing 11 peptides with average Mr bias <0.01%)
was used as an external standard, and the system was
re-calibrated after every 8 acquisitions. Thirteen stand-
ard sera were used for quality controls, and the resultant
testing peak had a coefficient of variation of < 30% indi-
cative of acceptable protocol stability. The instrumental
parameters were: a) positive ion spectrometry b) ion
source accelerating voltage of 20 kV, c) ion extraction
delay of 120 ns, d) the laser frequency of 25 Hz, e) the
highest detected protein Mr of 20,000, and f ) the
optimized range of M/Z 800-10,000 and average 400
point signals for each sample. Flex Analysis 3.0 software
was used for data acquisition and pre-processing to
obtain the average serum protein profiles of each group,
followed by multiplexed comparisons.
The acquired data of the protein peaks were analyzed by
the Anderson-Darling test, pairwise comparison t-test,
and the Wilcoxon test to determine whether differences
exist in candidate protein biomarkers levels betweensarcoidosis and non-sarcoidosis groups. In addition, the
ClinProt system including analytical software bundle,
the ClinProTools that comprise of three machine-
learning algorithms (Genetic Algorithm (GA), Supervised
Neural Network (SNN) and QuickClassifier (QC)) for
generating classification patterns of the serum protein
distributions. This package of machine-learning algorithms
is able to analyze serum protein profile of sarcoidosis
and non-sarcoidosis subjects as shown in Figure 1.
Identification of differentially expressed protein peaks by
LC-MS/MS
The sequence of differential peptide peaks between sar-
coidosis group and non-sarcoidosis groups was identified
by LC-MS/MS (NanoAquity UPLC liquid chromatograph,
Waters, USA; LTQ Orbitrap XL electrospray ionization
mass spectrometer, Thermo Fisher Scientific). All MS/MS
spectra were identified by using SEQUEST [v.28 (revision
12), Thermo Electron Corp.] against the human Inter-
national Protein Index (IPI) database. The searching
parameters were set up as follows: NoEnzyme, the vari-
able modification was oxidation of methionine, the pep-
tide mass tolerance was 5 ppm, and the fragment ions
tolerance was 1 Da. Positive protein identification was
accepted for a peptide with Xcorr of greater than or
equal to 3.00 for triply and 2.50 for doubly charged ions,
and all with ΔCn ≥ 0.1, peptide probability ≤ 0.001.
Detection of Serum Amyloid A (SAA) in serum
To follow up the finding by mass spectrometry, human
SAA ELISA assay (Y10903A, Human Serum amyloid A,
SAA ELISA KIT) was used to measure the SAA level in
64 serum samples from patients with sarcoidosis. 99 serum
samples were obtained from the comparison groups (26
healthy volunteers, 35 tuberculosis cases, 12 COPD cases,
14 interstitial lung disease cases and 12 lung cancer cases).
Twenty (20) of 64 sarcoidosis patients were classified as
the “treated” group, who had been successfully treated by
Figure 1 The acquired data of the protein peaks were statistically analyzed.
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cure. The remaining 44 patients were determined as
“untreated” sarcoidosis, who had clinical symptoms to
different extents but had not receive corticosteroid.Preliminary evaluation of the clinical performance
characteristics of the SAA
The receiver operating characteristic (ROC) curve was
plotted according to the SAA contents, as determined
by the ELISA with the values of SAA in the sarcoidosis
and non-sarcoidosis subjects. The optimal cut-off thresh-
old is determined by ROC as the maximal value of Youden
index (Youden index = sensitivity + specificity-1) for the
quantitative analysis.Detection of SAA in lung tissue
The streptavidin-perosidase (SP) immunohistochemical
assay was performed to detect the expression of SAA by
a SAA antibody (clone mc1; Dako; Carpinteria, CA, USA)
in tissue biopsies of a subset of our test subjects: 10
patients with sarcoidosis (lung in 2, subcutaneous granu-
lomas in 3, and lymph nodes in 5) and lung tissues of 10
patients with other lung diseases (tuberculosis in 2, organ-
izing pneumonia in 2, cryptococcal pneumonia in 2, lung
carcinoma in 4).Statistics
All experiments were carried out in triplicates, and the
data were presented as mean ± standard deviation (SD).
The statistical software SPSS 11.0 was used for data ana-
lysis. Independent-samples t test assuming equal variance
and ANOVA were performed with p < 0.05 indicated
statistically significant difference.
Results
Reproducibility of the ClinProt system
Two samples from patients with sarcoidosis and one
sample from a healthy control were used to verify repro-
ducibility of the ClinProt system. Proteins were detected
in these samples in a parallel experiment. The results
showed that under the above-mentioned experimental
conditions, M/Z bias was in a statistically acceptable
range of errors (coefficient of variation or CV < 30%).
Figure 2 shows the triplicate mass spectra of a represen-
tative serum sample at various time points. The overall
profiles of the 67 protein peaks were comparable. The
average CV was 13.5%.
Comparison of the mean serum protein profiles
In the range of M/Z 800-10,000, there were 8, 8 and 13
different protein peaks when the sarcoidosis subjects
were compared with healthy controls, tuberculosis subjects
and other lung disease subjects respectively. The protein
Figure 2 The triplicate serum mass spectra of a representative sample at various time points under the standard conditions. X-axis
represents mass to charge ratio, and Y-axis represents the intensity (expression levels).
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learning algorithms (GA, QC and SNN) to determine
whether the identification and predictive ability of classifi-
cation models in distinguishing sarcoidosis from the other
disease subjects and from healthy controls (Table 2).
Specifically, of the total 8 differential peaks between
the sarcoidosis group and tuberculosis group, 5 protein
peaks (M/Z 3,976.97; 3,955.19; 3,210.04; 3,159.37 and
3,280.43) were overexpressed in sarcoidosis versus the
other 3 (M/Z 2,901.48; 2,989.71 and 2,661.63) that were
more elevated and overexpressed in the tuberculosis
group. In our study, the SNN method achieved the best





Sarcoidosis vs. 3210, 2661, 3280, 2679↑; 91
healthy control 4268, 4397, 6433, 4211↓; 66
Sarcoidosis vs. 3976, 3955, 3210, 3159, 3280↑; 97
tuberculosis 2901, 2989, 2661↓; 75
Sarcoidosis vs. 2954, 2106, 4469, 3210,1279, 6631, 2933↑; 95
other lung
diseases control
5266, 5808, 5292, 5337, 5484. 5249↓. 82In addition, as shown in Figure 3, the expression level
of the protein peak M/Z 3,210 in the sarcoidosis group
was significantly higher than that of the non-sarcoidosis
groups (p < 0.05), but showed no significant differences
between the non-sarcoidosis groups (healthy control, tu-
berculosis, and other diseased subjects, p > 0.05), which
indicated that this is a disease-associated or specific pro-
tein for saroidosis.
M/Z 3,210 was identified as Serum amyloid A protein
The LC-MS/MS trapped a molecular species of M/Z
3,211.57 (M+H), and the tandem MS analysis in the sec-















Figure 3 The expression level of the protein peak M/Z 3,210. The mean intensity of different expressed proteins peak M/Z 3,210 in the
sarcoidosis group was significantly higher when compared to non-sarcoidosis groups (S: sarcoidosis group, N: healthy control, T: tuberculosis
group, C: diseased group).
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Human (3.45) database retrieved the consistent peptide
identity of "SLADQAANEWGRSGKDPNHFRPAGLPEKY",
which is the N-terminal 29 peptide of SAA (94-122; SAA,
IPI:IPI00552578.2 Gene_Symbol = SAA1; SAA2 Serum
amyloid A protein precursor) (Table 3).
Verification of SAA in the serum
Having the identified M/Z 3,210 as the N-terminal pep-
tide of SAA, next ELISA was employed to evaluate the
expression of SAA in serum of sarcoidosis and non-
sarcoidosis subjects. As shown in Figure 4, the levels of
SAA in serum of the sarcoidosis group (both treated
and untreated groups) were significantly elevated than
those of the non-sarcoidosis group (p < 0.05). ELISA
was performed to detect SAA in serum from the patients
with sarcoidosis and the higher levels of SAA were
more likely to be associated with sarcoidosis than with
non-sarcoidosis.
Evaluation of the usefulness of serum SAA levels for
clinical diagnosis of sarcoidosis by ROC
SAA in serum of 163 subjects (64 sarcoid and 99 non-
sarcoid) detected by semi- quantitative ELISA is plotted
to generate the ROC curve using the cutoff point of
101.98 μg/L. The optimal cut-off yields the best sensitiv-
ity of 96.3%, and specificity of 52.5%, respectively; and
the AUC of 0.763 (Figure 5).
Verification of SAA in the lung tissue of patients with
sarcoidosis
Immunohistochemical assay showed that SAA depositions
occurred in lung, subcutaneous and lymph node granulomasTable 3 The listed differential peaks to be identified
Scan(s) MH+ Peptide
1681 3211.57 SLADQAANEWGRSGKDPNHFRPAGLPEKY IPI:IPI00552578
Scan: scan number; MH+: the mass to charge ratio by adding H+; Reference: proteiof patients with sarcoidosis, and appeared more intense
in tissue staining than in the lungs of patients with
organized pneumonia, cryptococcal lung and lung can-
cer, respectively (Figure 6).
Discussion
The diagnosis of sarcoidosis is still a significant challenge
in China because of the need to exclude lung diseases that
are especially common in China (ie. TB, COPD, lung
cancer of which in patients with similar clinical and/or
radiographic findings). This is the first study demon-
strating potential effectiveness of protein profiling in
serum with ClinProt as a diagnostic tool for sarcoidosis
in ethnic Han Chinese. We confirm that the SAA serum
level and tissue expression of sarcoidosis are higher than
in other lung diseases.
Over the last decade, accumulated evidences in the
research of protein biomarkers of sarcoidosis have
shown that it is possible to find sarcoidosis-specific or
associated proteins through analysis of body fluids.
Researchers used to compare protein profiles from sar-
coidosis patients with healthy controls in specimens of
bronchoalveolar lavage fluid (BALF) [21-26]. However,
no further analysis for the positive identification of the
sarcoidosis-associated peak was performed. Collection of
blood is much less invasive than collection of BALF, and
not subject to variabilities of BALF collection such as
dilution and contamination by oropharyngeal secretions.
Several studies have reported novel serum biomarkers
in sarcoidosis. Bons JA and his colleagues from The
Netherlands first applied surface-enhanced laser desorp-
tion ioni-zation time-of-flight mass spectrometry (SELDI-
TOF-MS) to compare protein profiles from 35 sarcoidosisReference P (pep)
.2 Gene_symbol = SAA1;SAA2 Serum amyloid a protein precursor 1.56E-04
n code and name; Peptide: peptide sequence; P (pep): degree of confidence.
Figure 4 The SAA levels were significantly elevated in sarcoidosis group, detected by ELISA in serum. (a) The SAA levels of the
sarcoidosis group were significantly higher (p <0.05) than those of non-sarcoidosis groups. S: sarcoidosis group, N: healthy control, T: tuberculosis
group, C: diseased control group). (b) There was no significiant difference between treated and untreated groups.
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tial protein peak M/Z 17,377 was identified as the alpha-2
chain of haptoglobin, although the total haptoglobin level
in the serum detected by ELISA was not statistically
significant between the disease group and the controls.
In the same study, there were two other unidentified
serum proteins that were also up-regulated in sarcoid-
osis patients. Recently, Bargagli et al, using proteomic
tools found that serum concentrations of SAA were sig-
nificantly higher in sarcoidosis patients than in healthy
controls. They thought that SAA is likely one of the un-
identified biomarkers in Bons’s proteomic study [15,27].
This study is the first effort using the ClinProt system of
serum protein profiling in Chinese subjects to discoverFigure 5 The cutoff of SAA contents in serum detected by
semi-quantitative ELISA is used to determine sarcoidosis (n = 64)
and non-sarcoidosis (n = 99) of the receiver operating
characteristic (ROC) curve.new diagnostic biomarkers in sarcoidosis. The ClinProt
system is considered as more advanced technologies
than SELDI-TOF-MS [28]. We are charged with the
need to differentiate sarcoidosis from other similar
diseases with enrolling 37 patients with sarcoidosis, 20
healthy volunteers and otherwise non-sardoidosis diseases
in lung including tuberculosis, COPD, interstitial lung
disease and lung cancer as control. In our pilot study,
among the multiple differential protein peaks detected
by ClinProt-MALDI-TOF, the expression levels of M/Z
3,210 in the sarcoidosis group was significantly elevated
in peak height than those in non-sarcoidosis groups
(p < 0.05. Thus M/Z 3,210 was the potential candidate
biomarker, which was further analyzed by LC-MS/MS.
The investigations confirmed a 29 amino acid peptide se-
quence of “SLADQAANEWGRSGKDPNHFRPAGLPEKY”,
which corresponds to the N-terminal fragment of SAA.
SAA is an acute phase protein, which belongs to a
group of heterogeneous proteins of the apolipoprotein
family. It is possible that SAA could activate the NF-kB
signaling pathway through interactions with Toll-like
receptor 2 (TLR2), leading to the development of chronic
granuloma as has been recently reported by Chen et al
[14]. Although the underlying mechanism of the increase
in the secretion of SAA or the chemotatic tissue depos-
ition due to changes in the internal environment remain
unclear. Nonetheless these findings suggest that SAA
could be a potential biomarker for the diseases.
A literature survey indicates that besides sarcoidosis,
SAA is also over-expressed in several diseases such as
COPD [16], lung cancer [17], and other interstitial lung
diseases [18]. Our study showed that expression of SAA
was significantly higher in sarcoidosis than in the other
non-sarcoidosis disease groups (Figure 4). Furthermore,
we found that sarcoidosis patients also had increased tis-
sue levels of SAA, and it was deposited in the granu-
lomas of patients (Figure 6).
The optimal cutoff of the serum SAA concentration
obtained by the ROC analysis was 101.98 ng/ml yielding a
sensitivity of 96.3% and specificity of 52.5% for diagnosis,
Figure 6 Immunohistochemistry showed SAA deposition in lung, subcutaneous and lymph node granulomas of patients with
sarcoidosis, apparently thicker than the appearances in the lungs of patients with organized pneumonia, cryptococcal lung and
lung carcinoma.
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expanding the comparator groups to include patients with
other inflammatory lung disease, our results demonstrated
that SAA might be an important player in the develop-
ment of sarcoidosis. However, although SAA is sensitive, it
was less specific for the diseases tested in the study. This
means that it is not for confirmative or for ruling- in a
diagnosis of sarcoidosis.
A follow up question is whether the SAA is a marker
of disease activity or it was a sequel of the treatments?
As early as 1989, Rubinstein et al had shown that SAA
concentration in 25 sarcoidosis patients (13 cases with
“active sarcoidosis” and 12 cases with “inactive sarcoid-
osis”) and 94 healthy volunteers. He showed that SAA
concentrations in both types of sarcoidosis were signifi-
cantly higher than that of healthy controls. However,
SAA was of limited usefulness as a marker for disease
activity [13]. A report from Italy demonstrated that con-
centration of SAA in serum is significantly higher in
patients with sub-acute onset requiring prolonged and
multiple steroid treatments than in patients with sub
acute onset but not requiring therapy (p < 0.001). In this
study, we found that SAA is similarly increased in both
“treated” and “untreated” sarcoidosis, which implies that
SAA is not affected by the corticosteroid treatment.
Since the usefulness of multiple markers for diagnosis
is now widely recognized [8]. ClinProt software could be
used in combination with three different algorithms
(Supervised Neural Network (SNN); Genetic Algorithm
(GA) and QuickClassifier (QC) to create testable diag-
nostic models for classifying potential biomarkers with
respect to whether they are associated with the sarcoid-
osis. In this study, the SNN method has achieved the op-
timal classification of sarcoidosis and non-sarcoidosis
with efficiency of identification of 100%, and predictivecapability of 78.62%; 93.15%, and 69.24% of efficiency
of identification and predictive capability, respectively,
between the sarcoidosis and the healthy controls; and
100% and 81.62% of efficiency of identification and pre-
dictive capability, respectively, between the sarcoidosis
and the diseased comparator groups. The machine
learning algorithms greatly improved the efficiency in
identification of potential serum biomarkers for the
diagnosis of sarcoidosis when compared to the previous
study. GA mimics evolution in nature, together with
the SNN and the QC are univariate sorting algorithms,
which use the p-values at certain peak positions for
classification. Therefore, these ClinProt system-based
serological classification models can be applied to the
clinical diagnosis of diseases, providing additional valid-
ation methods. However, the current classification models
based on the ClinProt platform would be expensive and
complicated to operate in routine clinical settings. Thus
they are limited in wider clinical applications.
Conclusion
In summary, our results provide evidences that the SAA
expression profiles by ClinProt-MALDI-TOF technique
were different between the sarcoidosis and controls in
Chinese subjects. The finding that the elevation of the
SAA N-terminal peptide is associated with sarcodosis, is
confirmed by ELISA in serum and further verified by
immunohistochemical staining in lung tissue. Moreover
experimental data obtained with current study suggested
that multiple markers for diagnosis could be used in dif-
ferential diagnosis of sarcoidosis despite its limitation in
of its specificity.
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